Hypoactive Sexual Desire Disorder Clinical Trial
Official title:
Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
Verified date | February 2020 |
Source | Ivix LLX |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD). Patients will be randomized in 1:1 ratio to either BP101 or placebo arms.
Status | Completed |
Enrollment | 205 |
Est. completion date | January 23, 2019 |
Est. primary completion date | November 26, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 21 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Women aged from 21 to 50 years old, who have signed informed concent, with a regular menstrual cycle (STRAW stages -5 to -3). - Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the diagnosis of acquired generalized hypoactive sexual desire disorder (HSDD) according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria. - Current HSDD episode lasting not less than 24 weeks. - Not less than 15 scores according to the FSDS-R (Distress) Total Score. - Stable monogamous relationship with one sexually active male sexual partner lasting at least a year. The partner is physically available not less than 50% of time during a month. - Consent to attempt to have a sexual intercourse at least twice a month, if she has a desire. - Consent to complete a diary every day during the screening period and assessment of the baseline state (in this period diary records must cover =80% days), during the therapy and subsequent follow-up. - Consent to use adequate methods of contraception throughout the study. Exclusion Criteria: - Any prohibited treatments. - Other mental disorders or psychiatric diseases. - Diagnosed Decrease or loss of sexual desire (HSDD) is situational (reactive) or lifelong. - Score = 20 according to the Beck Depression Inventory during the screening. Patients with 16 to 19 scores according to Beck's inventory may be included in the study unless, in the investigator's opinion, an actual depressive disorder is observed in the patient. - Inflammatory diseases of pelvic organs, infections of the genitourinary system, cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal epithelium, precluding normal sexual activity. - Surgical interventions (other than cosmetic surgeries) on reproductive organs in past medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related perineal stitches, etc), resulting in pain/dyspareunia, and/or precluding sexual contacts, and/or requires hormonal replacement treatment, and/or lead to the loss of sensibility while sexual contact. - Pregnant and nursing women or non-lactating women during the first 12 months after childbirth. - Consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction, drug addiction or drug abuse in the past. One portion of an alcoholic drink means 360 ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | ????????? ??????????????? ??????????? ??????????? | Barnaul | |
Russian Federation | Kazan State Medical University | Kazan | |
Russian Federation | Kuban State Medical University | Krasnodar | |
Russian Federation | Central Clinical Hospital of the Russian Academy of Sciences | Moscow | |
Russian Federation | N.A. Alexeev Moscow Psychiatric Clinical Hospital #1 | Moscow | |
Russian Federation | National Medical Research Center of Obstetrics, Gynecology and Perinatology | Moscow | |
Russian Federation | National Medical Research Center of Psychiatry and Addiction named after V.P. Serbsky | Moscow | |
Russian Federation | Clinical Psychiatry Hospital ?1 | Nizhniy Novgorod | |
Russian Federation | Orenburg Regional Clinical Psychiatric Hospital No. 2 | Orenburg | |
Russian Federation | City psychiatric hospital ?7 named after academician I.P. Pavlov | Saint Petersburg | |
Russian Federation | Doctor SAN Ltd. | Saint Petersburg | |
Russian Federation | Leningrad Regional Narcological Dispensary | Saint Petersburg | |
Russian Federation | OrKli Hospital LLC | Saint Petersburg | |
Russian Federation | Research center Eco-Safety LLC | Saint Petersburg | |
Russian Federation | Samara Psychiatric Hospital | Samara | |
Russian Federation | Regional Clinical Psychiatric Hospital of St. Sofia | Saratov | |
Russian Federation | Engels Psycyatric hospital | Saratovskaya | |
Russian Federation | Clinic "Hundred Years" | Tomsk | |
Russian Federation | Bashkir State Medical University | Ufa | |
Russian Federation | Yaroslavl Regional Clinical Psychiatric Hospital | Yaroslavl' |
Lead Sponsor | Collaborator |
---|---|
Ivix LLX |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Satisfying sexual events | Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 weeks of treatment, compared with the baseline. | Baseline and 4 weeks of treatment | |
Secondary | Satisfying sexual events | Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 and 8 weeks of follow-up, compared with the baseline. | Baseline and 4 and 8 weeks of follow-up | |
Secondary | Orgasms | Change in the number of orgasms, standardized to the 28-day period, after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. | Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index total score | Change in the Female Sexual Function Index (FSFI) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI total score ranges from 2.0 to 36.0, where higher score represents better sexual function. FSFI total score is a sum of FSFI individual domains scores (individual domains are: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain). |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Desire domain score | Change in the Female Sexual Function Index (FSFI) Desire domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Desire domain score ranges from 1.2 to 6.0, where higher score represents better sexual desire. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Arousal domain score | Change in the Female Sexual Function Index (FSFI) Arousal domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Arousal domain score ranges from 0 to 6.0, where higher score represents better sexual arousal. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Lubrication domain score | Change in the Female Sexual Function Index (FSFI) Lubrication domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Lubrication domain score ranges from 0 to 6.0, where higher score represents better vaginal lubrication. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Orgasm domain score | Change in the Female Sexual Function Index (FSFI) Orgasm domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Orgasm domain score ranges from 0 to 6.0, where higher score represents better orgasm sensation. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Satisfaction domain score | Change in the Female Sexual Function Index (FSFI) Satisfaction domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Satisfaction domain score ranges from 0.8 to 6.0, where higher score represents better sexual satisfaction. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Function Index Pain domain score | Change in the Female Sexual Function Index (FSFI) Pain domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSFI Pain domain score ranges from 0 to 6.0, where higher score represents lower pain sensation during sexual intercourse. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Distress Scale-Revised Total score | Change in the Female Sexual Distress Scale-Revised (FSDS-R) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSDS-R total score ranges from 0 to 52, where higher score represents higher level of distress related to sexual activities. A score of =11 discriminates between women with female sexual disfunction (score of =11) and no female sexual disfunction (score of <11). |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Female Sexual Distress Scale-Revised Item 13 score | Change in the Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSDS-R Item 13 score ranges from 0 to 4, where higher score represents higher level of bother by low sexual desire. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Sexual function according to the Female Sexual Function questionnaire | Change in the Female Sexual Function questionnaire (FSF) score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. FSF score ranges from 0 to 36, where higher score represents better sexual function. |
Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement | The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement (PGI-I) after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline. | Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up | |
Secondary | Number of adverse events | Frequency of adverse events reporting, including serious adverse events, in treatment groups. | During 12 weeks after start of treatment (4 weeks of treatment and 8 weeks of follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02430987 -
Low Sexual Desire and Metabolic Syndrome
|
N/A | |
Completed |
NCT01432665 -
Lybrido for Female Sexual Dysfunction
|
Phase 2 | |
Terminated |
NCT00551785 -
Surveillance Study of Women Taking Intrinsa®
|
Phase 4 | |
Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
Recruiting |
NCT04179734 -
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
|
Phase 4 | |
Terminated |
NCT02770768 -
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
|
N/A | |
Completed |
NCT01235754 -
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT03287232 -
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT00384046 -
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
|
Phase 3 | |
Completed |
NCT00331123 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Recruiting |
NCT04943068 -
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
|
Phase 3 | |
Completed |
NCT01208038 -
Testosterone Patch's Effects on the Cardiovascular System and Libido
|
Phase 4 | |
Completed |
NCT00657501 -
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
|
Phase 3 | |
Completed |
NCT04336891 -
Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
|
||
Completed |
NCT01382719 -
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
|
Phase 2 | |
Recruiting |
NCT00916396 -
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
|
N/A | |
Completed |
NCT00331214 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT00338312 -
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Recruiting |
NCT02968342 -
Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women
|
Phase 4 |